STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
This study, called STOP-PKD, is looking into whether a medication called dapagliflozin can help people with a common genetic kidney condition known as Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD causes fluid-filled cysts to grow in the kidneys, leading to them not working as well over time. The study wants to see if dapagliflozin can slow down this loss of kidney function. Currently, there aren't many widely used treatments for ADPKD. This trial is comparing dapagliflozin to a 'dummy' pill (placebo) to find out if it's safe and effective. It's a large study, involving patients aged 18 to 60, and aims to provide clear answers about this potential new treatment.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
Autosomal Dominant Polycystic Kidney Disease, or ADPKD, is a genetic condition that causes many fluid-filled sacs, called cysts, to grow in your kidneys. Over time, these cysts can get bigger and more numerous, leading to the kidneys not working as well as they should. This can eventually lead to kidney failure, which is when the kidneys stop working completely and treatment like dialysis or a kidney transplant is needed. ADPKD is the most common genetic cause of kidney failure.
At the moment, there's only one approved treatment that can help slow down the disease, and it's not suitable for everyone. This means doctors are always looking for new and better ways to help people with ADPKD. Recently, a type of drug called SGLT2 inhibitors has been shown to help protect kidneys in people with other kidney conditions. However, people with ADPKD weren't included in those original studies, so we don't yet know if these drugs are helpful for them.
This study, called STOP-PKD, aims to find out if one of these SGLT2 inhibitor drugs, called dapagliflozin, can slow down the worsening of kidney function in people with ADPKD. Participants will either receive dapagliflozin or a matching dummy pill (placebo) for a period of time. Researchers will carefully check how their kidneys are working to see if the drug makes a difference. This research is really important because it could lead to another helpful treatment option for people living with ADPKD.
النقاط الرئيسية
- This study investigates if dapagliflozin can slow down kidney damage in ADPKD.
- It uses a 'dummy' pill (placebo) to accurately compare effects.
- Participation involves regular clinic visits for tests and health checks.
- People aged 18-60 with a specific range of kidney function may be eligible.
- This research could offer a new treatment option for ADPKD.
- You can stop participating at any time without affecting your usual care.
من قد يكون مؤهلاً؟
To join this study, you generally need to be an adult with ADPKD, aged between 18 and 60 years old. Your kidney function also needs to be within a specific range, showing that your kidneys are still working to some extent but also that your condition might be getting worse over time.
The research team will also look for signs that your ADPKD is likely to progress more quickly. This could be based on your specific genetic information, how quickly your kidney function has changed in the past, or how your cysts look on imaging scans.
There are also some reasons why you couldn't join. For example, if you're already taking certain other medications for ADPKD or have other serious health conditions like specific types of diabetes, uncontrolled high blood pressure, or a history of certain severe infections. Women who are pregnant, breastfeeding, or could become pregnant and are not using effective contraception also cannot participate.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك بين 18 و 60 سنة؟
- Do you have a diagnosis of ADPKD?
- Are your kidneys still working, but perhaps showing signs of getting worse?
- Are you able to take a daily pill?
- Are you not currently taking other specific ADPKD medications (like tolvaptan)?
- Are you not pregnant, breastfeeding, or planning to become pregnant without using effective contraception?
ماذا يتضمن المشاركة؟
If you decide to take part in this study, you'll be randomly assigned to either receive the study drug, dapagliflozin, or a matching dummy pill (placebo). This means neither you nor your study doctor will know which one you are taking until the end of the study. You'll take your study medication once a day.
Throughout the study, you'll have regular visits to the clinic. These visits will involve various assessments, such as blood and urine tests to check your kidney function, blood pressure measurements, and possibly imaging scans to look at your kidneys. These tests help the researchers understand how the medication is affecting your body. The study will last for a period of time, and you'll have follow-up visits to monitor your health. The medical team will explain the exact schedule of visits and tests during the consent process.
المخاطر والفوائد المحتملة
المواقع (27)
- Vorarlberger Krankenhaus-Betriebsgesellschaftالرمز البريدي المؤكدFeldkirch, Austria· لم يبدأ التوظيف بعد
- Medizinische Universitaet Innsbruckالرمز البريدي المؤكدإنسبروك، النمسا· لم يبدأ التوظيف بعد
- Universitaetsklinikum Aachen AöRالرمز البريدي المؤكدآخن، ألمانيا· التوظيف
- Charite Universitaetsmedizin Berlin KöRالرمز البريدي المؤكدبرلين، ألمانيا· التوظيف
- Universitätsklinikum Kölnالرمز البريدي المؤكدكولونيا، ألمانيا· التوظيف
- Klinikum Dortmund gGmbHالرمز البريدي المؤكددورتموند، ألمانيا· التوظيف
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöRالرمز البريدي المؤكددرسدن، ألمانيا· التوظيف
- Universitaetsklinikum Duesseldorf AöRالرمز البريدي المؤكددوسلدورف، ألمانيا· لم يبدأ التوظيف بعد
- Goethe University Frankfurtالرمز البريدي المؤكدفرانكفورت، ألمانيا· التوظيف
- Universitaetsmedizin Goettingenالرمز البريدي المؤكدغوتينغن، ألمانيا· لم يبدأ التوظيف بعد
- المركز الطبي الجامعي هامبورغ-إيبندورفالرمز البريدي المؤكدهامبورغ، ألمانيا· لم يبدأ التوظيف بعد
- الجامعة الطبية في هانوفرالرمز البريدي المؤكدهانوفر، ألمانيا· التوظيف
أسئلة شائعة
What is ADPKD?
ADPKD is a genetic condition where fluid-filled sacs, called cysts, grow in your kidneys, which can cause them to lose their function over time.
What is dapagliflozin?
Dapagliflozin is a drug that helps your kidneys remove sugar from your body. It has been shown to protect kidneys in people with other conditions, and this study wants to see if it helps with ADPKD.
ما هو الدواء الوهمي؟
A placebo is a 'dummy' pill that looks just like the study drug but contains no active medicine. It helps researchers check if the study drug is truly effective.
Will I know if I'm getting the real drug or the dummy pill?
No, this is a 'double-blind' study, meaning neither you nor your study doctor will know whether you are receiving dapagliflozin or the placebo until the study is over.
كم ستستغرق مدة الدراسة؟
The study's full duration will be explained by the research team if you are eligible and interested in participating.
كيفية معرفة المزيد
Roman-Ulrich Müller, Prof.
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.